ClinicalTrials.gov record NCT07329556

Skin Autofluorescence Assessment of Advanced Glycation End Products in Rheumatic Diseases

Record copied from ClinicalTrials.gov: Oct 10, 2026AI summaries generated: Sep 17, 2026

Evaluation of Advanced Glycation End Products Accumulation in Rheumatic Diseases Using Non-Invasive Skin Autofluorescence Measurements

About this page. This page shows the study's official ClinicalTrials.gov record ↗, with added help to make it easier to understand. We explain medical terms, highlight key details in plain language, and suggest questions you may want to ask the study team.

The record is periodically copied from ClinicalTrials.gov and may lag behind changes. AI summaries are checked by software, not a clinician.Read moreShow less

The official record is written by the study sponsor and published on ClinicalTrials.gov. It may not always reflect the latest changes. Before making any decisions, please confirm important information with the study team and your own healthcare team.

Where you see "AI summary", AI was used to create a plain-language explanation and software checked it against the source. It has not been reviewed by a clinician, so it may contain mistakes or leave out important details.

StatusNot yet recruitingThe study has been registered but has not started enrolling. Sites and contacts may not be listed yet.

Study typeObservationalA study in which researchers do not assign participants to a treatment or other intervention. They observe or measure what happens, which may include study visits, tests, questionnaires or a review of medical records.

Healthy volunteersAcceptedPeople who do not have the condition being studied who are allowed to take part. Some studies include both people with the condition and healthy volunteers; others may enrol only healthy volunteers.

Age18 years old to 75 years old

SexAll

AI summaryWhat this study is about, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

This observational case-control study compares skin autofluorescence, a non-invasive measure of advanced glycation end products (AGEs), between adults with various inflammatory rheumatic diseases and healthy volunteers. Each participant has a single baseline skin autofluorescence measurement; inflammatory markers are also considered. The study seeks to learn whether AGE burden differs between patient groups and controls and how it relates to inflammation and disease subtype.

What it is studying. Whether the amount of AGEs measured by non-invasive skin autofluorescence differs between people with inflammatory rheumatic diseases and healthy volunteers, and how those AGE levels relate to inflammatory blood markers and to different rheumatic disease subtypes.

What the researchers hope to learn. To improve understanding of AGE accumulation in different rheumatic diseases; to compare AGE levels across disease subtypes and with healthy controls; and to explore whether skin autofluorescence could be a useful non-invasive biomarker linked to inflammation.

What this study is about

The study's own summary, as published on ClinicalTrials.gov. Underlined terms have a short explanation.

Rheumatic diseases are chronic inflammatory conditions that can lead to long-term tissue damage and increased cardiovascular and metabolic risk. Advanced glycation end products (AGEs) are harmful molecules that accumulate in the body over time and are known to promote inflammation and oxidative stress. Increased AGE burden has been implicated in several chronic diseases; however, its role in rheumatic diseases has not been fully clarified. This observational, cross-sectional study aims to evaluate the accumulation of AGEs in patients with various rheumatic diseases compared with healthy individuals. AGE levels will be assessed non-invasively using skin autofluorescence measurements. By comparing AGE burden between patients and healthy controls, this study seeks to improve understanding of the potential role of AGEs in the pathophysiology of rheumatic diseases and to explore their usefulness as a non-invasive biomarker in clinical practice.

Eligibility

The criteria exactly as listed on ClinicalTrials.gov. Only the study team can say whether they apply to you.

Inclusion criteria

Age between 18 and 75 years
Diagnosis of an inflammatory rheumatic disease (including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, reactive arthritis, connective tissue diseases, Behçet disease, familial Mediterranean fever, or crystal arthropathies), confirmed by a rheumatologist
Healthy volunteers without a history of rheumatic or chronic inflammatory disease (for the control group)
Ability to undergo non-invasive skin autofluorescence measurement
Ability and willingness to provide written informed consent

Exclusion criteria

Diagnosis of diabetes mellitus (type 1 or type 2)
Chronic kidney disease with estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m²
Active malignancy or history of malignancy within the past 5 years
Presence of acute infection or acute inflammatory condition at the time of assessment
Secondary causes of systemic inflammation unrelated to the underlying rheumatic disease (e.g., uncontrolled endocrine disorders, chronic liver disease)
Use of medications known to markedly affect AGE accumulation or skin autofluorescence measurements (e.g., recent high-dose systemic glucocorticoids)
Pregnancy or breastfeeding
Presence of significant skin conditions (e.g., extensive dermatitis, scars, tattoos, or burns) at the measurement site that may interfere with skin autofluorescence assessment
Inability to comply with study procedures or to provide informed consent

Study description and what participation involves

The registry record has no detailed description beyond the summary above.

AI summaryWhat participation may involve, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

Take part in a single study visit that includes a non‑invasive skin autofluorescence measurement to assess advanced glycation end‑product (AGE) accumulation. Participants will have relevant clinical information recorded and systemic inflammatory markers (for example C‑reactive protein and erythrocyte sedimentation rate) assessed or recorded for comparison. You will be asked to give written informed consent and confirm you can undergo the skin measurement. There are no invasive procedures listed; the visit may include a review of medical history and current medications.

How the study is structured. Observational, prospective case-control study. Adults with diagnosed inflammatory rheumatic diseases form one group and age/sex-matched healthy volunteers form a control group. Participants attend a single study visit for a non-invasive skin autofluorescence measurement (using a validated AGE Reader device) and collection of routine inflammatory markers for comparison.

Questions you could ask

These questions are suggestions for a conversation with the study team or your own clinician, not advice.

This is an observational study, so the study itself gives no treatment. What would taking part involve for me, and would it change my usual care?
The registry says recruitment has not started. When is it expected to open, and can I register interest now?
No sites are listed on the registry yet. Where will the study take place?
Which of the eligibility criteria would need to be checked with tests before I could join?

More on familial Mediterranean fever

Clinical trials62 trials listed for familial Mediterranean feverEvery trial the registry lists for familial Mediterranean fever, with recruitment status, phase and sites, updated from ClinicalTrials.gov.See all trials →Research updatesWhat changed in familial Mediterranean fever researchLatest monthly update: September 2026. Includes: Colchicine form change. New research summarized each month in plain language, with links to every source paper.Read the latest update →

Important dates

Study start: Jan 15, 2026 (estimated)
Primary completion: Jan 15, 2027 (estimated)
Study completion: Apr 15, 2027 (estimated)
Target enrollment: 300 participants (estimated)
Last updated on registry: Jan 9, 2026
Data verified: Oct 10, 2026

Sponsor and research team

The lead sponsor funds and oversees the trial. A pharmaceutical or biotech company sponsor typically means the study is testing that company's drug or device; a hospital, university, or government agency usually indicates investigator-initiated or publicly funded research.

Lead sponsor: Bursa City Hospital
Principal investigator: Taner Dandinoğlu, Principal Investigator
Bursa City Hospital

Central study contact

If you're interested in participating, the central contact can answer general questions about the study — including eligibility requirements and how to find a recruiting site near you. Actual eligibility is determined by the site's medical team.

Altuğ Güner, MD 📞 +905337414088 ✉ altugguner555@gmail.com

Participating sites

Study locations have not been posted on ClinicalTrials.gov yet. This study is not yet recruiting, so sites may be added when recruitment begins. The central study contact above may be able to tell you about planned sites.

Terms used on this page · explanations by MedicalUpdates.ai

biomarker: Something measurable in the body, such as a blood test result or an imaging finding, that indicates how a condition or treatment is behaving.
control group: The group the study treatment is compared with. It may receive a placebo, an existing treatment (active comparator), a sham procedure, or no intervention.
written informed consent: The process of explaining a study, including its risks and what participation involves, so that a person can decide freely whether to take part. Consent is usually documented in writing, and a participant can choose to leave the study later.
estimated glomerular filtration rate: A blood-test estimate of how well the kidneys are filtering. Lower numbers mean reduced kidney function; many studies set a minimum value.
glucocorticoids: Steroid medicines, such as prednisone, that reduce inflammation. Studies often require a stable dose at entry or measure whether the study treatment allows the dose to be reduced.
Inclusion Criteria: The conditions a person must meet to be considered for the study, for example a confirmed diagnosis, an age range or a test result.
Exclusion Criteria: The conditions that rule a person out even if they meet the inclusion criteria, for example other illnesses, certain medicines or pregnancy.

The study record on this page is reproduced from ClinicalTrials.gov, a database of the U.S. National Library of Medicine, where it was submitted by the study sponsor. MedicalUpdates.ai does not own this content, is not affiliated with or endorsed by ClinicalTrials.gov, NIH, or the U.S. Government, and does not verify the record. Plain-language notes, the glossary and the questions above are added by this site; text in the boxes marked "AI summary" was written by an AI model and may contain errors. Registry records change over time. Check the original record for the current version and discuss eligibility or participation with a qualified healthcare professional.

← Back to clinical trials